Leap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer

Reuters

2025/10/20

Leap <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer

Leap Therapeutics Inc. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable $(MSS)$ colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology (ESMO) Congress 2025. In the DKK1-high patient population, the objective response rate $(ORR)$ was 38.0% in the Sirexatamab Arm compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE00287) on October 20, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576853490"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576853490\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576853490?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576853490","market":"nz","top_or_hot":-1,"title":"Leap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LPTX\">Leap Therapeutics Inc</a>. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology (ESMO) Congress 2025. In the DKK1-high patient population, the objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> was 38.0% in the Sirexatamab <a href=\"https://laohu8.com/S/ARM\">Arm</a> compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE00287) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-20 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LPTX\">Leap Therapeutics Inc</a>. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology (ESMO) Congress 2025. In the DKK1-high patient population, the objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> was 38.0% in the Sirexatamab <a href=\"https://laohu8.com/S/ARM\">Arm</a> compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE00287) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL9Cctc3:1","article_id":"2576853490","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576853490","pubTimestamp":1760958063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Leap Therapeutics Inc. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab , an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable  colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology  Congress 2025. In the DKK1-high patient population, the objective response rate  was 38.0% in the Sirexatamab Arm compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpose","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4563":"昨日强势股","BK4505":"高瓴资本持仓"},"translate_title":"Leap Therapeutics报告Sirexatamab可显着改善DKK1高结直肠癌的预后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LPTX":0.9},"content_text":"Leap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer\n    \n\nLeap Therapeutics Inc. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable $(MSS)$ colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology (ESMO) Congress 2025. In the DKK1-high patient population, the objective response rate $(ORR)$ was 38.0% in the Sirexatamab Arm compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE00287) on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}